Search results for "Schedule"

showing 10 items of 567 documents

Narrative writing competence and internal state terms of young adults clinically diagnosed with childhood attention deficit hyperactivity disorder

2013

Abstract Objective The first objective of this study was to compare the written expression competence of young adults with attention deficit hyperactivity disorder (ADHD) with that of young adults without ADHD on three types of measures: indicators of the story's microstructure with regard to productivity and morphosyntax; indicators of the macrostructure (story grammar); and expressions of the mental states of the story's characters (internal state language). The second objective consisted of determining the relationships among the different narrative writing measures and the ADHD behavior ratings of inattention and hyperactivity obtained using the family observer report. Method The sample…

MaleMental Status ScheduleAdolescentWritingmedia_common.quotation_subjectSeverity of Illness IndexDevelopmental psychologyCorrelationYoung Adultmental disordersSeverity of illnessDevelopmental and Educational PsychologymedicineHumansAttention deficit hyperactivity disorderNarrativeYoung adultCompetence (human resources)Languagemedia_commonNarrationGrammarmedicine.diseaseClinical PsychologyAttention Deficit Disorder with HyperactivityFemaleMental Status SchedulePsychologyResearch in Developmental Disabilities
researchProduct

Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age

2016

Background: A serogroup B meningococcal vaccine (4CMenB) is licensed for infant use in countries including Canada, Australia and those of the European Union. Data on serum bactericidal antibody (hSBA) waning and the ideal timing of a "toddler" booster dose are essential to optimize vaccine utilization. Methods: An open-labeled, multicenter phase-2b follow-on European study conducted from 2009 to 2012. Participants previously receiving 4CMenB with routine vaccines at 2, 4 and 6 or 2, 3 and 4 months (246Con and 234Con) or at 2, 4 and 6 months intercalated with routine vaccines (246Int) received a booster dose at 12, 18 or 24 months. 4CMenB-naive "Control" participants aged 12, 18 or 24 months…

MaleMicrobiology (medical)Pediatricsmedicine.medical_specialtypaediatricpersistence of immunityImmunization SecondaryMeningococcal VaccinesMeningococcal vaccineBooster doseMeningitis MeningococcalNeisseria meningitidis Serogroup BPaediatric; Persistence of immunity; Serogroup B meningococcal vaccine; Serum bactericidal activity;Serum bactericidal activityserum bactericidal activity03 medical and health sciences0302 clinical medicine030225 pediatricsOutcome Assessment Health CaremedicineHumansmedia_common.cataloged_instance030212 general & internal medicineToddlerEuropean unionSerogroup B meningococcal vaccineImmunization Schedulemedia_commonMedicine(all)MeningococcalBooster (rocketry)business.industryVaccinationInfantbactericidal antibodiesmedicine.diseaseAntibodies BacterialEuropeVaccinationInfectious DiseasesImmunizationPaediatricChild PreschoolPediatrics Perinatology and Child HealthPersistence of immunityFemaleImmunizationbusinessMeningitisPediatric Infectious Disease Journal
researchProduct

Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV combination vaccine Co-administered with a hib conjugate vaccine either as a si…

2004

A combined DTPa-HBV-IPV/Hib vaccine containing diphtheria (D), tetanus (T), acellular pertussis (Pa), hepatitis B (HBV) and types 1, 2 and 3 inactivated polioviruses (IPV) extemporaneously mixed with a conjugated Haemophilus influenzae type b (Hib) vaccine (Group 1) was compared to the DTPa-HBV-IPV and Hib vaccines (Group 2) administered separately at 3, 5 and 11 months of age (n = 440). A microneutralization assay was used to detect antibodies against the 3 polio virus types (cut-off 1:8 dil), RIA for anti-HBs antibodies (cut-off 10 mIU/ml) and ELISA for antibodies against all other vaccine antigens (cut-off: 0.1 IU/ml for anti-tetanus and anti-diphtheria antibodies; 5 El.U/ml for antibodi…

MaleMicrobiology (medical)Vaccination scheduleEnzyme-Linked Immunosorbent AssayAntibodies ViralInjections IntramuscularRisk Assessmentcomplex mixturesConjugate vaccineGermanyConfidence IntervalsmedicineHumansHepatitis B VaccinesVaccines CombinedBacterial CapsulesDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesProbabilityImmunity CellularReactogenicityGeneral Immunology and MicrobiologyTetanusbusiness.industryImmunogenicityDiphtheriaPolysaccharides BacterialVaccinationInfantGeneral MedicineHib Conjugate vaccinemedicine.diseaseAntibodies BacterialVirologyHexavalent combination; DTPa-HBV-IPV combination vaccine; Hib Conjugate vaccineVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesItalyHib vaccineHexavalent combinationImmunologyFemalebusinessDTPa-HBV-IPV combination vaccineFollow-Up StudiesScandinavian Journal of Infectious Diseases
researchProduct

Clarithromycin Versus Azithromycin in the Treatment of Mediterranean Spotted Fever in Children: A Randomized Controlled Trial

2002

We conducted an open-label randomized controlled trial to compare the efficacy and safety of clarithromycin (15/mg/kg/day in 2 divided doses for 7 days) with those of azithromycin (10 mg/kg/day in 1 dose for 3 days) in the treatment of children with Mediterranean spotted fever. Until now, there has not been a gold-standard therapy for this rickettsial disease in children. Eighty-seven children were randomized to receive 1 of the 2 drugs. The mean time to defervescence (+/- standard deviation) was 46.2+/-36.4 h in the clarithromycin group and 39.3+/-31.3 h in the azithromycin group. These differences were not statistically significant and both drugs were equally well-tolerated. Clarithromyci…

MaleMicrobiology (medical)medicine.medical_specialtyAdolescentErythromycinAzithromycinBoutonneuse FeverAzithromycinDrug Administration Schedulelaw.inventionRandomized controlled triallawClarithromycinClarithromycinInternal medicinemedicineHumansChildAntibacterial agentMediterranean spotted fever Clarithromycin azithromycinbusiness.industryInfantmedicine.diseaseAnti-Bacterial AgentsSurgerySpotted feverBoutonneuse feverRickettsia conoriiTreatment OutcomeInfectious DiseasesRickettsiosisChild PreschoolFemalebusinessmedicine.drugClinical Infectious Diseases
researchProduct

Minimal clinically important difference and minimal detectable change of the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0…

2020

Objectives: The aim of this study is to estimate a minimal clinically important difference (MCID) and a minimal detectable change (MDC) of the 12-item WHODAS 2.0 amongst patients with chronic musculoskeletal pain. Design: Cross-sectional cohort study. Setting: Outpatient Physical and Rehabilitation Medicine clinic. Subjects: A total of 1988 consecutive patients with musculoskeletal pain. Interventions: A distribution-based approach was employed to estimate a minimal clinically important difference, a minimal detectable change, and a minimal detectable percent change (MDC%). Results: The mean age of the patients was 48 years, and 65% were women. The average intensity of pain was 6,3 (2.0) po…

MaleMusculoskeletal painSchedule2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)WHODASPhysical Therapy Sports Therapy and Rehabilitationminimal detectable changetuki- ja liikuntaelimetWorld healthDisability assessmentCohort StudiesDisability EvaluationMusculoskeletal PainHumansMedicineskin and connective tissue diseasesmusculoskeletal painPain Measurementbusiness.industryMinimal clinically important differenceminimal clinically important differenceRehabilitationkipuMiddle AgedCross-Sectional StudiesPhysical therapyFemalesense organsWhodasChronic PainbusinessData Collection toolsClinical Rehabilitation
researchProduct

Floor and ceiling effects of the World Health Organization Disability Assessment Schedule 2.0 among patients with chronic musculoskeletal pain

2019

The aim of this study was to investigate the floor and ceiling effects of 12-item World Health Organization Disability Assessment Schedule 2.0 (WHODAS). This was a cross-sectional survey study at a university’s physical and rehabilitation medicine outpatient clinic of 1988 patients with chronic musculoskeletal pain. Floor and ceiling effects were calculated as relative frequencies of the lowest or the highest possible scores for each item. The probit plotting method was used to detect the non-normality of distribution of the total score graphically. A significant floor effect of 15–79% was observed in all 12 WHODAS 2.0 items. A substantial floor effect for total score was also detected grap…

MaleMusculoskeletal painSchedulemedicine.medical_specialtyPsychometricsarviointimenetelmätStatistics as TopicPhysical Therapy Sports Therapy and RehabilitationCeiling (cloud)World Health OrganizationWorld healthDisability assessmentDisability EvaluationMusculoskeletal PainSurveys and QuestionnairesHumansMedicineOutpatient clinictoimintarajoitteetmusculoskeletal painWorld Health Organization Disability Assessment Schedule 2.0business.industryRehabilitationReproducibility of Resultsta3141Survey researchMiddle AgedCross-Sectional StudiesPhysical therapykrooninen kipuFemaleChronic PainbusinessInternational Journal of Rehabilitation Research
researchProduct

Inhibition of myosin light chain kinase reduces brain edema formation after traumatic brain injury.

2010

The role of the endothelial contractile apparatus in the process of brain edema formation after brain trauma is not characterized. Phosphorylation of myosin light chains by myosin light chain kinases (MLCK) activates endothelial contractile elements and results in a rearrangement of the cytoskeleton. This may enhance post-traumatic blood-brain barrier dysfunction. In order to investigate the role of the MLCK on brain edema formation and blood-brain barrier permeability after brain injury, mice were anesthetized and subjected to a controlled cortical impact (CCI). MLCK expression is significantly up-regulated after CCI with a maximum 12 h post-injury. Specific inhibition of MLCK by ML-7 resu…

MaleMyosin light-chain kinaseMyosin Light ChainsTime FactorsEndotheliumIntracranial PressureTraumatic brain injuryCentral nervous systemBrain Edemamacromolecular substancesBrain damageNaphthalenesBlood–brain barrierBiochemistryNeuroprotectionDrug Administration ScheduleFunctional LateralityStatistics NonparametricCerebral edemaCellular and Molecular NeuroscienceMicemedicineAnimalsEnzyme InhibitorsMyosin-Light-Chain KinaseNeurologic Examinationbusiness.industryAzepinesmedicine.diseaseConstrictionCell biologyMice Inbred C57BLDisease Models Animalmedicine.anatomical_structureGene Expression RegulationBlood-Brain BarrierBrain Injuriesmedicine.symptombusinessNeuroscienceEvans BlueJournal of neurochemistry
researchProduct

Reinstatement of Morphine-Induced Conditioned Place Preference in Mice by Priming Injections

2004

To construct a model of relapse of drug abuse in mice, the induction, we evaluated the extinction and reinstatement of morphine-induced place preference. In Experiment 1, we examined the effects of morphine (0, 2, 3, 5, 10, 20 and 40 mg/kg) in the conditioned place preference (CPP) paradigm. Mice showed CPP with 5, 10, 20 and 40 mg/kg. In Experiment 2, we evaluated the effects of two different extinction procedures. After conditioning with 40 mg/kg of morphine, the mice underwent daily extinction sessions of 60 or 15 min of duration. CPP was extinguished after seven and nine sessions, respectively. In Experiment 3, we tested the reinstating effects of several priming doses of morphine. Mice…

MaleNarcoticsReinforcement SchedulePharmacologyArticleExtinction Psychologicallcsh:RC321-571MiceRewardmedicineAnimalslcsh:Neurosciences. Biological psychiatry. NeuropsychiatryDose-Response Relationship DrugMorphineExtinction (psychology)Conditioned place preferenceDose–response relationshipNeurologyAnesthesiaMorphineConditioning OperantConditioningNeurology (clinical)PsychologyReinforcement PsychologyPriming (psychology)Injections Intraperitonealmedicine.drugNeural Plasticity
researchProduct

MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis

2008

Objective: To prospectively validate MRI activity and neutralising anti-interferon antibody (NAb) during the first 6 months of interferon β treatment as response indicators in multiple sclerosis (MS). Methods: Patients with relapsing–remitting MS were followed during the first 2 years of treatment. Neurological assessments were performed every 3 months or when a relapse was suspected. MRI scans performed at baseline and at 3, 4, 5 and 6 months after the start of treatment were assessed centrally for disease activity: new T2 or gadolinium enhancing T1 lesions. NAb were assessed using the MxA protein assay; positivity was defined as two consecutive titres ⩾20 NU/ml. We evaluated the predictiv…

MaleNeutralising antibodyMULTICENTERPLACEBO-CONTROLLED TRIALGUIDELINESGastroenterologyDOUBLE-BLINDInterferon βMAGNETIC-RESONANCEProspective StudiesNeurologic ExaminationbiologyBrainIMPAIRMENTMiddle AgedPredictive valueMagnetic Resonance ImagingRecombinant ProteinsPsychiatry and Mental healthTreatment OutcomeSettore MED/26 - NeurologiaFemaleAntibodyInterferon beta-1bAdultmedicine.medical_specialtyDIAGNOSTIC-CRITERIAInjections SubcutaneousAntibodiesDrug Administration ScheduleDisease activityMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicNeutralization TestsInternal medicinemedicineHumansInterferon betabusiness.industryMultiple sclerosisDISABILITYMSInterferon-betamedicine.diseaseConfidence intervalSurgerybiology.proteinSurgeryNeurology (clinical)businessFollow-Up Studies
researchProduct

A specific anti-aggressive effect of repeatedly administered lobeline.

2002

The effects of chronic treatments with nicotinic agonists on agonistic encounters have received little attention. The effects of repeated (for 10 days) SC administration of (-)-lobeline (9.3, 18.6 and 37.2 micromol/kg) and (-)-nicotine (0.93, 1.86 and 3.72 micromol/kg) were evaluated using the mouse isolation-induced aggression model. Individually housed OF1 male mice served as experimental animals and were confronted by 'standard opponents'. Each mouse was tested only once on the last day of the repeated drug treatment. Videotaped agonistic encounters were analysed estimating the times allocated to 11 behavioural categories. Repeated treatment with the highest dose of lobeline diminished a…

MaleNicotineMedicine (miscellaneous)Male micePharmacologyMotor ActivityDrug Administration ScheduleNicotinechemistry.chemical_compoundMiceRepeated treatmentAgonistic behaviourmedicineAnimalsLobelineMotor activityNicotinic AgonistsPharmacologyDose-Response Relationship DrugAggressionAggressionPsychiatry and Mental healthNicotinic agonistchemistrySocial IsolationLobelinemedicine.symptomPsychologyAgonistic Behaviormedicine.drugAddiction biology
researchProduct